page 1 hiv treatment-as-prevention (tasp) for people who use illicit drugs and implications for hcv...
TRANSCRIPT
Page 1
HIV Treatment-as-Prevention (TasP) for people who use illicit drugs and implications for HCV TasP: The North American experience
M-J MILLOYResearch scientist, British Columbia Centre for Excellence in HIV/AIDS; Assistant professor, Division of AIDS, Department of Medicine, University of BC
8th International AIDS Society Conference on HIV pathogenesis, Treatment & PreventionVancouver, 22 July 2015
Page 2
I have no conflicts of interest to declare.
Page 3
Page 4
Page 5
Figure 1: Gains in life expectancy among ART-treated HIV+ in North America
Page 6
HIV+ people who use drugs have not benefitted equally from HAART
– Lower rates of access to HAART– Lower levels of adherence to HAART– Higher rates of discontinuation– Elevated rates of suboptimal HIV/AIDS
treatment outcomes
Page 7
Page 8
After IAS 2015: Will people who use drugs in North America reap the full benefit from TasP/90-90-90?
Page 9
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 19960
50
100
150
200
250
300
350
400
450
Figure 1: New HIV diagnoses in Vancouver among PWID, 1985 to 1996
Page 10
HIV outbreak among PWID in Vancouver’s Downtown Eastside (DTES)• Proximate: Shift to cocaine injection• “Deadly public policy”
– Housing policies– Needle exchange restrictions– Police enforcement and incarceration– Changes in resource economy
Page 11
Scale-up of HIV/AIDS treatment for people who use drugs
– 2005: Immediate initiation of PWID in HIV/AIDS clinical guidelines
– 2010: STOP HIV/AIDS pilot project in DTES• Seek, Test, Treat and Retain (STTR)
– Ongoing: province-wide TasP-based effort
Page 12
AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS)
– Open longitudinal prospective cohort – HIV+ people who use illicit drugs– Recruited from community settings in
Vancouver’s Downtown Eastside (DTES)– Complementary cohort to VIDUS– Ongoing since 2005
Page 13
ACCESS study: Baseline– 817 participants; mean age = 43 (IQR: 37-48)– 535 (66%) male; 466 (57%) Caucasian– Homeless/marginally housed: 586 (73%)– Live in the DTES: 528 (65%)– Recently incarcerated: 188 (15%)– Illicit drug use patterns:
• 136 (17%) ≥ daily heroin injectors• 292 (36%) ≥ daily crack cocaine smokers
Page 14
Engagement in HIV care, ACCESS study, 2006 – 2012 (n = 805)
Page 15
Incidence of resistance, ACCESS study, 2006 - 2012
Page 16
Plasma HIV non-detectability, ACCESS, 2006 to 2013, (n = 805 participants)
Page 17
Page 18
Page 19
CD4 cell count at treatment initiation, ACCESS, 2005 to 2013 (n = 357)
Page 20
Maximally-assisted therapy (MAT)– “To improve access and adherence to ART by
minimizing barriers through a multidisciplinary care approach”
– Directly-observed therapy; on-site MMT– 15% ACCESS participants in MAT– Among people with ≥ 1 day ART in last 180:
• 90% MAT participants achieved optimal adherence• 63% non-MAT achieved optimal adherence
Page 21
HIV Cascade of Care among ACCESS– Improvements in ART engagement, ART
adherence and viral suppression– Relevant patient-level factors:
• Initiation of ART at higher CD4 cell counts;• Adherence supports, including methadone co-
dispensation;• Decrease in pill burden
– Other factors?
Page 22
Page 23
Page 24
Factors associated with plasma HIV RNA rebound (n = 277)
Page 25
HIV treatment initiation among PWID:
– Illicit drug use patterns not associated with treatment initiation
– Barriers to treatment initiation:
• Illicit income generation (drug dealing, sex work, binning, etc.)
• Incarceration
Page 26
HIV Cascade of Care among ACCESS– Improvements in ART engagement, ART
adherence and viral suppression– Possible effect on HIV transmission patterns?
Page 27
Figure 2: HIV seroconversion rate, 1996 to 2012, VIDUS
96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 130
10
20
30
40
50
60
70
80
90
Page 28
Page 29
85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 120
50
100
150
200
250
300
350
New HIV diagnoses in BC among injection drug users, 1985 – 2012 (BC Centre for Disease Control)
Page 30
>96% decrease in rate of new HIV infections in DTES associated with:
– Scale-up of HAART– Scale-up of low-barrier methadone– Needle exchange to needle distribution– Opening supervised injection facility– Heroin prescription trial
Page 31
TasP initiatives in North America:– Province of British Columbia– San Francisco, California– New York State
Page 32
TasP initiatives in North America:– Province of British Columbia– San Francisco, California– New York State
Limited commitments to scale up TasP
Limited data on HIV care cascade
Page 33
Figure 3: HIV care cascade, ALIVE study, Baltimore MD, 1998 - 2011
Page 34
Page 35
Page 36
Page 37
“If you would have asked me last year if I was for a needle exchange program, I would have said you’re nuts… I thought, just like a lot of people do, that it’s enabling — that you’re just giving needles out and assisting them in their drug habit.”
Page 38
“If you would have asked me last year if I was for a needle exchange program, I would have said you’re nuts… I thought, just like a lot of people do, that it’s enabling — that you’re just giving needles out and assisting them in their drug habit.” — Public health nurse, Indiana
Page 39
“If you would have asked me last year if I was for a needle exchange program, I would have said you’re nuts… I thought, just like a lot of people do, that it’s enabling — that you’re just giving needles out and assisting them in their drug habit.” — Public health nurse, Indiana.“But then I did the research on it, and there’s 28 years of research to prove that it actually works.”
Page 40
Despite decades of evidence…– HIV outbreak driven by poor distribution to
sterile syringes ongoing in Indiana, Saskatchewan
– Methadone remains sub-optimally delivered in many settings
– Correctional settings remain key drivers of poor access to HIV prevention and treatment
– 1 public Supervised Injection Facility
Page 41
TREATMENT-AS-PREVENTION– Vancouver: TasP treatment scale-up associated
with improvements in HIV care cascade and declines in new HIV infections
– Limited commitment to TasP scale-up in North American settings; limited data on HIV care cascade
– Repeating failures of HAART, PEP, PrEP, etc.?
Page 42
HIV PREVENTION IN NORTH AMERICA– Ongoing preventable HIV outbreaks– Criminalization limits optimal HIV/AIDS treatment
and prevention– Further research not needed on effectiveness of
TasP, HAART, MMT, SIF, etc.– Need to identify barriers to optimal delivery of all
HIV prevention tools for people who use drugs in all settings
Page 43
“Reinstating the [US federal government] ban [on needle exchange funding] is murderous. It's saying that people who use drugs should contract fatal and expensive diseases and die....this is a truly shameful moment, when we go backward instead of forward, and let a politics of ignorance, of stigma, of hate, win out over compassion, science and a desire for a healthy community.”
Laura Thomas, Drug Policy Alliance
Page 44
Acknowledgements• ACCESS study participants for contributions to the research• Current and past researchers and staff• ACCESS supported by United States National Institutes of Health
(R01-DA021525)• M-JSM supported in part by US NIH (R01-DA021525)